Midjourney unveils full-body ultrasonic scan spa

Midjourney announced a new business unit, Midjourney Medical, and unveiled the Midjourney Scanner, which the company calls an "Ultrasonic CT" or full-body ultrasound. According to Midjourney's website and blog post, the scanner images a person by lowering them into a shallow pool while a ring of sensors emits and records ultrasonic waves, producing whole-body acoustic tomography scans. Midjourney's stated production target is a scan time under 60 seconds; independent reporting (TechTimes) indicates the current Gen-1 prototype takes approximately 20 minutes per scan, having been tested on a reported ~12 people as of announcement. The company has posted a long-term goal of deploying 50,000 scanners worldwide by 2031, with a total scanning capacity of 1 billion scans per month, and plans a flagship spa in San Francisco at end of 2027. Midjourney's materials describe the spa as including hot tubs, saunas, and cold plunges alongside multiple scanners.

Butterfly Network (NYSE: BFLY), a semiconductor-based ultrasound device maker, issued a press release confirming the arrangement. The current prototype incorporates 40 Butterfly Ultrasound-on-Chip imaging modules per system, licensed under a co-development agreement; future generations are expected to use substantially more modules. Butterfly disclosed the deal terms in an SEC Form 8-K on November 17, 2025, which stated up to $74 million in expected payments to Butterfly over a five-year term. The collaboration is enabled through Butterfly's "Butterfly Embedded" licensing initiative (formerly Octiv). Butterfly CEO Joseph DeVivo publicly stated the arrangement represents "a potentially meaningful commercial opportunity for Butterfly" (Butterfly Network press release, June 18, 2026).

The Midjourney Scanner currently has no FDA clearance. Midjourney states it will initially offer body-composition maps rather than diagnostic outputs, and will submit test results to the FDA for expanded capabilities. Radiologists and clinical observers have publicly questioned the marketing claims: noted concerns include the gap between the prototype's current scan time and the stated 60-second goal, the small number of people tested at announcement, no published clinical validation, and potential overdiagnosis risks associated with mass whole-body screening without established clinical criteria (The Verge, The Next Web, expert commentary via RadiologyBusiness and social media).

Ultrasonic CT in this context refers to acoustic tomography - using many small transducers to emit and record sound waves from multiple angles, then reconstructing a volumetric image. This is mechanically different from conventional diagnostic ultrasound (single-probe) and from X-ray CT or MRI. AI is used primarily for post-processing tasks such as segmentation and labeling rather than raw image formation (The Next Web, The Verge). Industry observers note multi-angle ultrasound arrays can increase throughput and reduce cost versus single-probe systems, but producing diagnostic parity with MRI would require rigorous clinical validation on specific endpoints - MRI and ultrasound differ fundamentally in contrast mechanisms, resolution through bone, and tissue-type sensitivity.

Key indicators include whether Midjourney registers or publishes clinical studies, submits for FDA clearance or approval, achieves the 60-second scan target in a production device, publishes comparative diagnostic accuracy data, and establishes data governance and patient privacy frameworks for large-scale consumer scanning. The progress of the Butterfly Network commercial milestones tied to the $74M agreement is also a measurable signal of program viability.

Primary claims about scanner design, deployment goals, and spa concept come from Midjourney's own blog and website. The Butterfly Network press release and SEC filing independently corroborate the chip partnership and deal structure. Clinical and performance limitations are drawn from independent reporting; the 20-minute prototype scan time has not been disputed by Midjourney as of these reports.